Abstract
The prevalence of osteoarthritis (OA) and the burden associated with the disease are steadily increasing worldwide, representing a major public health challenge for the coming decades. The lack of specific treatments for OA has led to it being recognized as a serious disease that has an unmet medical need. Advances in the understanding of OA pathophysiology have enabled the identification of a variety of potential therapeutic targets involved in the structural progression of OA, some of which are promising and under clinical investigation in randomized controlled trials. Emerging therapies include those targeting matrix-degrading proteases or senescent chondrocytes, promoting cartilage repair or limiting bone remodelling, local low-grade inflammation or Wnt signalling. In addition to these potentially disease-modifying OA drugs (DMOADs), several targets are being explored for the treatment of OA-related pain, such as nerve growth factor inhibitors. The results of these studies are expected to considerably reshape the landscape of OA management over the next few years. This Review describes the pathophysiological processes targeted by emerging therapies for OA, along with relevant clinical data and discussion of the main challenges for the further development of these therapies, to provide context for the latest advances in the field of pharmaceutical therapies for OA.
Key points
-
Osteoarthritis (OA) is a very common and severely debilitating disease with an unmet medical need, and new drugs are needed to alleviate OA symptoms and/or prevent structural progression.
-
Several drugs, such as sprifermin and MIV-711, have been shown to prevent cartilage loss or protect subchondral bone in OA, and thus represent potential disease-modifying OA drugs (DMOADs).
-
The clinical benefits of the positive structural outcomes observed with DMOADs, as well as their long-term safety, remain unclear.
-
Nerve growth factor inhibitors (such as tanezumab and fasinumab) improve pain and function in severe knee or hip OA, but are associated with an increased risk of rapidly progressive OA.
-
Biologic drugs (including IL-1β and TNF inhibitors) and bisphosphonates have yielded disappointing results in OA.
-
The clinical heterogeneity of OA is one of the major challenges for the development of DMOADs, as different phenotypes could require specific therapeutics.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745–1759 (2019).
Wallace, I. J. et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc. Natl Acad. Sci. USA 114, 9332–9336 (2017).
Hunter, D. J., Schofield, D. & Callander, E. The individual and socioeconomic impact of osteoarthritis. Nat. Rev. Rheumatol. 10, 437–441 (2014).
Safiri, S. et al. Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann. Rheum. Dis. 79, 819–828 (2020).
Bannuru, R. R. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 27, 1578–1589 (2019).
Gregori, D. et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA 320, 2564–2579 (2018).
McAlindon, T. E. et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317, 1967–1975 (2017).
Kolasinski, S. L. et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 72, 220–233 (2020).
Leopoldino, A. O. et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst. Rev. 2, CD013273 (2019).
Roberts, E. et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann. Rheum. Dis. 75, 552–559 (2016).
da Costa, B. R. et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev. 9, CD003115 (2014).
Fuggle, N. et al. Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36, 129–143 (2019).
Krebs, E. E. et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 319, 872–882 (2018).
Zeng, C. et al. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA 321, 969–982 (2019).
Bannuru, R. R. et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann. Intern. Med. 162, 46–54 (2015).
da Costa, B. R. et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 390, e21–e33 (2017).
Bally, M. et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 357, j1909 (2017).
Nissen, S. E. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 375, 2519–2529 (2016).
Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
Atiquzzaman, M., Karim, M. E., Kopec, J., Wong, H. & Anis, A. H. Role of nonsteroidal antiinflammatory drugs in the association between osteoarthritis and cardiovascular diseases: a longitudinal study. Arthritis Rheumatol. 71, 1835–1843 (2019).
Jüni, P. et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst. Rev. 10, CD005328 (2015).
Zeng, C. et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage 27, 855–862 (2019).
Rutjes, A. W. et al. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann. Intern. Med. 157, 180–191 (2012).
Honvo, G. et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36, 101–127 (2019).
US Food and Drug Administration. Osteoarthritis: structural endpoints for the development of drugs (FDA, 2018).
Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. B. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 64, 1697–1707 (2012).
Stampella, A., Monteagudo, S. & Lories, R. Wnt signaling as target for the treatment of osteoarthritis. Best Pract. Res. Clin. Rheumatol. 31, 721–729 (2017).
Conaghan, P. G., Cook, A. D., Hamilton, J. A. & Tak, P. P. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat. Rev. Rheumatol. 15, 355–363 (2019).
Styrkarsdottir, U. et al. Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis. Nat. Genet. 50, 1681–1687 (2018).
Tachmazidou, I. et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat. Genet. 51, 230–236 (2019).
Zengini, E. et al. Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis. Nat. Genet. 50, 549–558 (2018).
Hochberg, M. C. et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA 322, 1360–1370 (2019).
Conaghan, P. G. et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized, placebo-controlled study. Ann. Intern. Med. 172, 86–95 (2019).
Bedson, J. & Croft, P. R. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet. Disord. 9, 116 (2008).
Eckstein, F. et al. Comparison of radiographic joint space width and magnetic resonance imaging for prediction of knee replacement: a longitudinal case-control study from the Osteoarthritis Initiative. Eur. Radiol. 26, 1942–1951 (2016).
Troeberg, L. & Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta 1824, 133–145 (2012).
Glasson, S. S. et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434, 644–648 (2005).
Little, C. B. et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum. 60, 3723–3733 (2009).
Stanton, H. et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434, 648–652 (2005).
Neuhold, L. A. et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. 107, 35–44 (2001).
Krzeski, P. et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res. Ther. 9, R109 (2007).
Vandenbroucke, R. E. & Libert, C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat. Rev. Drug Discov. 13, 904–927 (2014).
Malfait, A. M. & Tortorella, M. D. The “elusive DMOAD”: aggrecanase inhibition from laboratory to clinic. Clin. Exp. Rheumatol. 37 (Suppl. 120), 130–134 (2019).
Clement-Lacroix, P. et al. ADAMTS-5 inhibition with the potent and highly selective inhibitor GLPG1972 results in strong disease-modifying OA drug effects in the rat meniscectomy model [abstract]. Osteoarthritis Cartilage 26, S26 (2018).
Clement-Lacroix, P. et al. GLPG1972: a potent, selective, orally available adamts-5 inhibitor for the treatment of OA [abstract]. Osteoarthritis Cartilage 25, S58–S59 (2017).
van der Aar, E. M. et al. ADAMTS-5 inhibitor GLPG1972, a potential new treatment in osteoarthritis, shows favorable safety, pharmacokinetics and pharmacodynamics in healthy subjects [abstract]. Osteoarthritis Cartilage 26, S310 (2018).
Lalande, A. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics in healthy male Japanese subjects of the ADAMTS-5 inhibitor S201086/GLPG1972, a potential new treatment in OA [abstract]. Arthritis Rheumatol. 71 (2019).
Siebuhr, A. et al. The anti-ADAMTS-5 nanobody®, M6495, protects against cartilage breakdown in cartilage and synovial joint tissue explant models [abstract]. Osteoarthritis Cartilage 26, S187 (2018).
Werkmann, D. et al. In vitro characterization of the ADAMTS-5 specific nanobody® M6495 [abstract]. Osteoarthritis Cartilage 26, S178 (2018).
Guehring, H. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody®, M6495, in healthy male subjects: a phase I, placebo-controlled, first-in-human study [abstract]. Arthritis Rheumatol. 71 (2019).
Jeon, O. H., David, N., Campisi, J. & Elisseeff, J. H. Senescent cells and osteoarthritis: a painful connection. J. Clin. Invest. 128, 1229–1237 (2018).
Loeser, R. F., Collins, J. A. & Diekman, B. O. Ageing and the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12, 412–420 (2016).
Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23, 775–781 (2017).
Hsu, B. et al. Safety, tolerability, pharmacokinetics, and clinical outcomes following single-dose IA administration of UBX0101, a senolytic MDM2/p53 interaction inhibitor, in patients with knee OA [abstract]. Arthritis Rheumatol. 71 (2019).
Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18–28 (2018).
Zheng, W. et al. Fisetin inhibits IL-1beta-induced inflammatory response in human osteoarthritis chondrocytes through activating SIRT1 and attenuates the progression of osteoarthritis in mice. Int. Immunopharmacol. 45, 135–147 (2017).
Ellsworth, J. L. et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 10, 308–320 (2002).
Moore, E. E. et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 13, 623–631 (2005).
Mori, Y. et al. Identification of fibroblast growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling. J. Biol. Chem. 289, 10192–10200 (2014).
Gigout, A. et al. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthritis Cartilage 25, 1858–1867 (2017).
Reker, D. et al. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. J. Transl. Med. 15, 250 (2017).
Lohmander, L. S. et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 66, 1820–1831 (2014).
Eckstein, F., Wirth, W., Guermazi, A., Maschek, S. & Aydemir, A. Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging. Arthritis Rheumatol. 67, 2916–2922 (2015).
Roemer, F. W. et al. Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial. BMC Musculoskelet. Disord. 17, 267 (2016).
Gühring, H. et al. OP0010 cartilage thickness modification with sprifermin in knee osteoarthritis patients translates into symptomatic improvement over placebo in patients at risk of further structural and symptomatic progression: post-hoc analysis of the phase II FORWARD trial. Ann. Rheum. Dis. 78, 70–71 (2019).
van der Kraan, P. M. The changing role of TGFbeta in healthy, ageing and osteoarthritic joints. Nat. Rev. Rheumatol. 13, 155–163 (2017).
Noh, M. J. et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). Cytotherapy 12, 384–393 (2010).
Ha, C. W., Noh, M. J., Choi, K. B. & Lee, K. H. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy 14, 247–256 (2012).
Guermazi, A. et al. Structural effects of intra-articular TGF-β1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial. BMC Musculoskelet. Disord. 18, 461 (2017).
Lee, B. et al. Results of a phase II study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-beta1. J. Knee Surg. 33, 167–172 (2019).
Kim, M. K. et al. A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients. Hum. Gene Ther. Clin. Dev. 29, 48–59 (2018).
Harrell, C. R., Markovic, B. S., Fellabaum, C., Arsenijevic, A. & Volarevic, V. Mesenchymal stem cell-based therapy of osteoarthritis: current knowledge and future perspectives. Biomed. Pharmacother. 109, 2318–2326 (2019).
Xing, D. et al. Intra-articular injection of mesenchymal stem cells in treating knee osteoarthritis: a systematic review of animal studies. Osteoarthritis Cartilage 26, 445–461 (2018).
Emadedin, M. et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy 20, 1238–1246 (2018).
Freitag, J. et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen. Med. 14, 213–230 (2019).
Kim, S. H. et al. Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of the knee: a meta-analysis of randomized controlled trials. Arch. Orthop. Trauma. Surg. 139, 971–980 (2019).
Lee, W. S., Kim, H. J., Kim, K. I., Kim, G. B. & Jin, W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase iib, randomized, placebo-controlled clinical trial. Stem Cell Transl. Med. 8, 504–511 (2019).
Pers, Y. M. et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. Stem Cell Transl. Med. 5, 847–856 (2016).
De Bari, C. & Roelofs, A. J. Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis. Curr. Opin. Pharmacol. 40, 74–80 (2018).
Decker, R. S. et al. Cell origin, volume and arrangement are drivers of articular cartilage formation, morphogenesis and response to injury in mouse limbs. Dev. Biol. 426, 56–68 (2017).
Roelofs, A. J. et al. Joint morphogenetic cells in the adult mammalian synovium. Nat. Commun. 8, 15040 (2017).
ter Huurne, M. et al. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum. 64, 3604–3613 (2012).
Goldring, S. R. & Goldring, M. B. Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone crosstalk. Nat. Rev. Rheumatol. 12, 632–644 (2016).
Zhen, G. et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med. 19, 704–712 (2013).
Funck-Brentano, T. et al. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol. 66, 3028–3039 (2014).
Fang, H. et al. Early changes of articular cartilage and subchondral bone in the DMM mouse model of osteoarthritis. Sci. Rep. 8, 2855 (2018).
Zhu, S. et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J. Clin. Invest. 129, 1076–1093 (2019).
Aso, K. et al. Associations of symptomatic knee osteoarthritis with histopathologic features in subchondral bone. Arthritis Rheumatol. 71, 916–924 (2019).
Nwosu, L. N. et al. Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA. Osteoarthritis Cartilage 25, 858–865 (2017).
Dearmin, M. G., Trumble, T. N., Garcia, A., Chambers, J. N. & Budsberg, S. C. Chondroprotective effects of zoledronic acid on articular cartilage in dogs with experimentally induced osteoarthritis. Am. J. Vet. Res. 75, 329–337 (2014).
Hayami, T. et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 50, 1193–1206 (2004).
Khorasani, M. S. et al. Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res. Ther. 17, 30 (2015).
Lampropoulou-Adamidou, K. et al. Chondroprotective effect of high-dose zoledronic acid: an experimental study in a rabbit model of osteoarthritis. J. Orthop. Res. 32, 1646–1651 (2014).
Mohan, G. et al. Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort. Osteoarthritis Cartilage 21, 1595–1604 (2013).
Siebelt, M. et al. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. Bone 66, 163–170 (2014).
Funck-Brentano, T. et al. Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One 7, e33543 (2012).
Kadri, A. et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann. Rheum. Dis. 69, 1533–1538 (2010).
Zhu, S. et al. Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats. Bone 53, 340–349 (2013).
Roman-Blas, J. A. et al. Phenotype may obtain major benefit from bone-acting agents. Semin. Arthritis Rheum. 43, 421–428 (2014).
Vaysbrot, E. E., Osani, M. C., Musetti, M. C., McAlindon, T. E. & Bannuru, R. R. Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 26, 154–164 (2018).
Damman, W. et al. Bone marrow lesions and synovitis on MRI associate with radiographic progression after 2 years in hand osteoarthritis. Ann. Rheum. Dis. 76, 214–217 (2017).
Felson, D. T. et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann. Intern. Med. 139, 330–336 (2003).
Haugen, I. K. et al. MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. Ann. Rheum. Dis. 75, 117–123 (2016).
Yusuf, E., Kortekaas, M. C., Watt, I., Huizinga, T. W. & Kloppenburg, M. Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann. Rheum. Dis. 70, 60–67 (2011).
Cai, G. et al. Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial. JAMA 323, 1456–1466 (2020).
Deveza, L. A. et al. Efficacy of bisphosphonates in specific knee osteoarthritis subpopulations: protocol for an OA Trial Bank systematic review and individual patient data meta-analysis. BMJ Open 8, e023889 (2018).
Laslett, L. L., Kingsbury, S. R., Hensor, E. M., Bowes, M. A. & Conaghan, P. G. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann. Rheum. Dis. 73, 824–830 (2014).
Neogi, T., Li, S., Peloquin, C., Misra, D. & Zhang, Y. Effect of bisphosphonates on knee replacement surgery. Ann. Rheum. Dis. 77, 92–97 (2018).
Haj-Mirzaian, A. et al. Bisphosphonates intake and its association with changes of periarticular bone area and three-dimensional shape: data from the Osteoarthritis Initiative (OAI). Osteoarthritis Cartilage 26, 564–568 (2018).
Heidari, B. & Babaei, M. Therapeutic and preventive potential of vitamin D supplementation in knee osteoarthritis. ACR Open Rheumatol. 1, 318–326 (2019).
Arden, N. K. et al. The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial. Osteoarthritis Cartilage 24, 1858–1866 (2016).
Jin, X. et al. Effect of Vitamin D supplementation on tibial cartilage volume and knee pain among patients with symptomatic knee osteoarthritis: a randomized clinical trial. JAMA 315, 1005–1013 (2016).
McAlindon, T. et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA 309, 155–162 (2013).
Perry, T. A. et al. Effect of Vitamin D supplementation on synovial tissue volume and subchondral bone marrow lesion volume in symptomatic knee osteoarthritis. BMC Musculoskelet. Disord. 20, 76 (2019).
Zheng, S. et al. Maintaining vitamin D sufficiency is associated with improved structural and symptomatic outcomes in knee osteoarthritis. Am. J. Med. 130, 1211–1218 (2017).
Sanghi, D. et al. Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial. Clin. Orthop. Relat. Res. 471, 3556–3562 (2013).
Jin, X. et al. Effect of vitamin D supplementation on pain and physical function in patients with knee osteoarthritis (OA): an OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis. BMJ Open 10, e035302 (2020).
Bossard, M. J. et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 271, 12517–12524 (1996).
Drake, F. H. et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271, 12511–12516 (1996).
Hou, W. S. et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 46, 663–674 (2002).
Konttinen, Y. T. et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 46, 953–960 (2002).
Dejica, V. M. et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am. J. Pathol. 173, 161–169 (2008).
Mort, J. S. et al. Early cathepsin K degradation of type II collagen in vitro and in vivo in articular cartilage. Osteoarthritis Cartilage 24, 1461–1469 (2016).
Hayami, T., Zhuo, Y., Wesolowski, G. A., Pickarski, M. & Duong, L. T. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 50, 1250–1259 (2012).
Kozawa, E. et al. Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. Arthritis Rheum. 64, 454–464 (2012).
Soki, F. N. et al. Articular cartilage protection in Ctsk−/− mice is associated with cellular and molecular changes in subchondral bone and cartilage matrix. J. Cell Physiol. 233, 8666–8676 (2018).
McClung, M. R. et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 7, 899–911 (2019).
Lindstrom, E. et al. The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. J. Transl. Med. 16, 56 (2018).
Robinson, W. H. et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12, 580–592 (2016).
Hill, C. L. et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann. Rheum. Dis. 66, 1599–1603 (2007).
Stoppiello, L. A. et al. Structural associations of symptomatic knee osteoarthritis. Arthritis Rheumatol. 66, 3018–3027 (2014).
Sarmanova, A., Hall, M., Moses, J., Doherty, M. & Zhang, W. Synovial changes detected by ultrasound in people with knee osteoarthritis - a meta-analysis of observational studies. Osteoarthritis Cartilage 24, 1376–1383 (2016).
Atukorala, I. et al. Synovitis in knee osteoarthritis: a precursor of disease? Ann. Rheum. Dis. 75, 390–395 (2016).
Felson, D. T. et al. Synovitis and the risk of knee osteoarthritis: the MOST Study. Osteoarthritis Cartilage 24, 458–464 (2016).
Roemer, F. W. et al. What comes first? Multitissue involvement leading to radiographic osteoarthritis: magnetic resonance imaging-based trajectory analysis over four years in the Osteoarthritis Initiative. Arthritis Rheumatol. 67, 2085–2096 (2015).
Wang, X. et al. Quantitative assessment of knee effusion-synovitis in older adults: association with knee structural abnormalities. Arthritis Rheumatol. 68, 837–844 (2016).
Conaghan, P. G. et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann. Rheum. Dis. 69, 644–647 (2010).
Wenham, C. Y. et al. A randomized, double-blind, placebo-controlled trial of low-dose oral prednisolone for treating painful hand osteoarthritis. Rheumatology 51, 2286–2294 (2012).
Kroon, F. P. B. et al. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet 394, 1993–2001 (2019).
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H. & Foster, C. S. Long-term side effects of glucocorticoids. Expert Opin. Drug Saf. 15, 457–465 (2016).
Conaghan, P. G. et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J. Bone Jt. Surg. Am. 100, 666–677 (2018).
Conaghan, P. G. et al. Brief report: a phase IIb trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intraarticular injection in knee osteoarthritis. Arthritis Rheumatol. 70, 204–211 (2018).
Kraus, V. B. et al. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthritis Cartilage 26, 34–42 (2018).
Russell, S. J. et al. Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study. Rheumatology 57, 2235–2241 (2018).
Hartmann, K. et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiol. Rev. 96, 409–447 (2016).
Kompel, A. J. et al. Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought? Radiology 293, 656–663 (2019).
Leung, Y. Y., Huebner, J. L., Haaland, B., Wong, S. B. S. & Kraus, V. B. Synovial fluid pro-inflammatory profile differs according to the characteristics of knee pain. Osteoarthritis Cartilage 25, 1420–1427 (2017).
Sohn, D. H. et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res. Ther. 14, R7 (2012).
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J. P. & Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7, 33–42 (2011).
Chevalier, X. et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61, 344–352 (2009).
Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).
Kloppenburg, M. et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann. Rheum. Dis. 78, 413–420 (2019).
Fleischmann, R. M. et al. A phase II trial of lutikizumab, an anti-interleukin-1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol. 71, 1056–1069 (2019).
van Dalen, S. C. et al. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage 25, 385–396 (2017).
Nasi, S., Ea, H. K., So, A. & Busso, N. Revisiting the role of interleukin-1 pathway in osteoarthritis: interleukin-1α and -1β, and NLRP3 inflammasome are not involved in the pathological features of the murine menisectomy model of osteoarthritis. Front. Pharmacol. 8, 282 (2017).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Schieker, M. et al. Effects of interleukin-1β inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 173, 509–515 (2020).
Wittoek, R. et al. Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study. Ann. Rheum. Dis. 77, 310–311 (2018).
Loef, M. et al. TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years. Rheumatology 57, 1917–1924 (2018).
Aitken, D. et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis — the HUMOR trial. Osteoarthritis Cartilage 26, 880–887 (2018).
Chevalier, X. et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 74, 1697–1705 (2015).
Verbruggen, G., Wittoek, R., Vander Cruyssen, B. & Elewaut, D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann. Rheum. Dis. 71, 891–898 (2012).
Kloppenburg, M. et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77, 1757–1764 (2018).
Leung, Y. Y. et al. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Osteoarthritis Cartilage 26, 631–640 (2018).
Larsson, S., Englund, M., Struglics, A. & Lohmander, L. S. Interleukin-6 and tumor necrosis factor alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscectomy. Osteoarthritis Cartilage 23, 1906–1914 (2015).
Goekoop, R. J. et al. Low innate production of interleukin-1β and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage 18, 942–947 (2010).
Livshits, G. et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum. 60, 2037–2045 (2009).
Stannus, O. et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 18, 1441–1447 (2010).
Latourte, A. et al. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann. Rheum. Dis. 76, 748–755 (2017).
Ryu, J. H. et al. Interleukin-6 plays an essential role in hypoxia-inducible factor 2alpha-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum. 63, 2732–2743 (2011).
Cook, A. D. et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res. Ther. 14, R199 (2012).
Schett, G. et al. A phase IIa study of anti-GM-CSF antibody GSK3196165 in subjects with inflammatory hand osteoarthritis [abstract]. Arthritis Rheumatol. 70 (2018).
Achuthan, A. et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J. Clin. Invest. 126, 3453–3466 (2016).
Li, T. et al. TGF-beta type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis. Sci. Transl. Med. 11, eaan2585 (2019).
Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. Gene delivery to joints by intra-articular injection. Hum. Gene Ther. 29, 2–14 (2018).
Nusse, R. & Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017).
Lories, R. J., Corr, M. & Lane, N. E. To Wnt or not to Wnt: the bone and joint health dilemma. Nat. Rev. Rheumatol. 9, 328–339 (2013).
Lambert, C. et al. Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. Arthritis Rheumatol. 66, 960–968 (2014).
Nakamura, Y., Nawata, M. & Wakitani, S. Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am. J. Pathol. 167, 97–105 (2005).
Lories, R. J. et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum. 56, 4095–4103 (2007).
Monteagudo, S. et al. DOT1L safeguards cartilage homeostasis and protects against osteoarthritis. Nat. Commun. 8, 15889 (2017).
Thysen, S., Luyten, F. P. & Lories, R. J. Loss of Frzb and Sfrp1 differentially affects joint homeostasis in instability-induced osteoarthritis. Osteoarthritis Cartilage 23, 275–279 (2015).
Zhu, M. et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum. 58, 2053–2064 (2008).
Zhu, M. et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J. Bone Miner. Res. 24, 12–21 (2009).
van den Bosch, M. H. et al. Induction of canonical Wnt Signaling by synovial overexpression of selected wnts leads to protease activity and early osteoarthritis-like cartilage damage. Am. J. Pathol. 185, 1970–1980 (2015).
Nalesso, G. et al. WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis. Ann. Rheum. Dis. 76, 218–226 (2017).
Lietman, C. et al. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight 3, e96308 (2018).
Deshmukh, V. et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 26, 18–27 (2018).
Deshmukh, V. et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 27, 1347–1360 (2019).
Yazici, Y. et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage 25, 1598–1606 (2017).
Yazici, Y. et al. Results from a 52 week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, Wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis [abstract]. Arthritis Rheumatol. 69 (2017).
Yazici, Y. et al. Efficacy and safety from a phase 2b trial of SM04690, a novel, intra-articular, Wnt pathway inhibitor for the treatment of osteoarthritis of the knee [abstract]. Arthritis Rheumatol. 70 (2018).
Gossec, L. et al. The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis Cartilage 19, 147–154 (2011).
Malfait, A. M. & Schnitzer, T. J. Towards a mechanism-based approach to pain management in osteoarthritis. Nat. Rev. Rheumatol. 9, 654–664 (2013).
Obeidat, A. M., Miller, R. E., Miller, R. J. & Malfait, A. M. The nociceptive innervation of the normal and osteoarthritic mouse knee. Osteoarthritis Cartilage 27, 1669–1679 (2019).
Neogi, T. et al. Association of joint inflammation with pain sensitization in knee osteoarthritis: the multicenter osteoarthritis study. Arthritis Rheumatol. 68, 654–661 (2016).
Brenn, D., Richter, F. & Schaible, H. G. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum. 56, 351–359 (2007).
Richter, F. et al. Tumor necrosis factor causes persistent sensitization of joint nociceptors to mechanical stimuli in rats. Arthritis Rheum. 62, 3806–3814 (2010).
Neogi, T. et al. Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: trait or state? Ann. Rheum. Dis. 74, 682–688 (2015).
Steen Pettersen, P. et al. Peripheral and central sensitization of pain in individuals with hand osteoarthritis and associations with self-reported pain severity. Arthritis Rheumatol. 71, 1070–1077 (2019).
Stefanik, J. J. et al. Changes in pain sensitization after bariatric surgery. Arthritis Care Res. 70, 1525–1528 (2018).
Miller, R. E. et al. Chemogenetic inhibition of pain neurons in a mouse model of osteoarthritis. Arthritis Rheumatol. 69, 1429–1439 (2017).
Chen, L. et al. Efficacy and tolerability of duloxetine in patients with knee osteoarthritis: a meta-analysis of randomised controlled trials. Intern. Med. J. 49, 1514–1523 (2019).
Osani, M. C. & Bannuru, R. R. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. Korean J. Intern. Med. 34, 966–973 (2019).
Weng, C., Xu, J., Wang, Q., Lu, W. & Liu, Z. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a systematic review and meta-analysis. Osteoarthritis Cartilage 28, 721–734 (2020).
Woolf, C. J., Safieh-Garabedian, B., Ma, Q. P., Crilly, P. & Winter, J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62, 327–331 (1994).
Mantyh, P. W., Koltzenburg, M., Mendell, L. M., Tive, L. & Shelton, D. L. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 115, 189–204 (2011).
Tominaga, M. et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21, 531–543 (1998).
Seidel, M. F., Herguijuela, M., Forkert, R. & Otten, U. Nerve growth factor in rheumatic diseases. Semin. Arthritis Rheum. 40, 109–126 (2010).
Miller, R. E., Block, J. A. & Malfait, A. M. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr. Opin. Rheumatol. 29, 110–118 (2017).
von Loga, I. S. et al. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis. Ann. Rheum. Dis. 78, 672–675 (2019).
Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521–1531 (2010).
Tive, L. et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J. Pain Res. 12, 975–995 (2019).
Roemer, F. W. & Guermazi, A. Imaging atlas for eligibility and on-study safety of potential joint adverse events in anti-NGF studies. Osteoarthritis Cartilage 23, S1–S2 (2015).
Hochberg, M. C. et al. When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 68, 382–391 (2016).
Belanger, P. et al. From the cover: evaluation of the effects of tanezumab, a monoclonal antibody against nerve growth factor, on the sympathetic nervous system in adult cynomolgus monkeys (Macaca fascicularis): a stereologic, histomorphologic, and cardiofunctional assessment. Toxicol. Sci. 158, 319–333 (2017).
Schnitzer, T. J. et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA 322, 37–48 (2019).
Berenbaum, F. et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann. Rheum. Dis. 79, 800–810 (2020).
Hochberg, M. C. et al. Subcutaneous tanezumab versus NSAID for the treatment of osteoarthritis: joint safety events in a randomized, double-blind, active-controlled, 80-week, phase-3 study [abstract]. Arthritis Rheumatol. 71 (2019).
Dakin, P. et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 71, 1824–1834 (2019).
Huskisson, E. C., Berry, H., Gishen, P., Jubb, R. W. & Whitehead, J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritis. J. Rheumatol. 22, 1941–1946 (1995).
Rashad, S. et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 2, 519–522 (1989).
Reijman, M. et al. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum. 52, 3137–3142 (2005).
Ding, C., Cicuttini, F. & Jones, G. Do NSAIDs affect longitudinal changes in knee cartilage volume and knee cartilage defects in older adults? Am. J. Med. 122, 836–842 (2009).
Nakata, K. et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage 26, 1263–1273 (2018).
LaBranche, T. P. et al. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann. Rheum. Dis. 76, 295–302 (2017).
Li, Z. et al. Fracture repair requires TrkA signaling by skeletal sensory nerves. J. Clin. Invest. 129, 5137–5150 (2019).
Tomlinson, R. E. et al. NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice. Proc. Natl Acad. Sci. USA 114, E3632–E3641 (2017).
Watt, F. E. et al. Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. Osteoarthritis Cartilage 27, 1590–1598 (2019).
Krupka, E., Jiang, G. L. & Jan, C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. Osteoarthritis Cartilage 27, 1599–1607 (2019).
Simone, D. A., Nolano, M., Johnson, T., Wendelschafer-Crabb, G. & Kennedy, W. R. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J. Neurosci. 18, 8947–8959 (1998).
Stevens, R. M. et al. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Arthritis Rheumatol. 71, 1524–1533 (2019).
Arsenault, P. et al. NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. Pain Rep. 3, e696 (2018).
Carlesso, L. C. & Neogi, T. Identifying pain susceptibility phenotypes in knee osteoarthritis. Clin. Exp. Rheumatol. 37, 96–99 (2019).
Deveza, L. A., Nelson, A. E. & Loeser, R. F. Phenotypes of osteoarthritis: current state and future implications. Clin. Exp. Rheumatol. 37, 64–72 (2019).
Author information
Authors and Affiliations
Contributions
A.L. wrote the article. All authors researched data for the article, made a substantial contribution to discussion of content and reviewed or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
A.L. has received consultancy fees from Pfizer. M.K. has acted as a consultant for Abbvie, Flexion, GlaxoSmithKline, Kiniksa, Levicept, Merck Serono and Pfizer, with fees paid to her institution; she has received royalties from Wolters Kluwer for contributing to Up-to-Date and from Springer Verlag for contributing to “Reumatologie en klinische immunologie”; and she has received grant funding from the Dutch Arthritis Association, European League Against Rheumatism and IMI/APPROACH. P.R. has received consultancy fees from BioIberica, Expanscience, Genévrier, Labrha, Pierre Fabre and Pfizer.
Additional information
Peer review information
Nature Reviews Rheumatology thanks C. Ding and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Latourte, A., Kloppenburg, M. & Richette, P. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol 16, 673–688 (2020). https://doi.org/10.1038/s41584-020-00518-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-00518-6
This article is cited by
-
Attenuation of osteoarthritis progression via locoregional delivery of Klotho-expressing plasmid DNA and Tanshinon IIA through a stem cell-homing hydrogel
Journal of Nanobiotechnology (2024)
-
Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development
Nature Reviews Rheumatology (2024)
-
Toll-like receptor activation regulates the paracrine effect of adipose-derived mesenchymal stem cells on reversing osteoarthritic phenotype of chondrocytes
Molecular Biology Reports (2024)
-
Dioscin alleviates the progression of osteoarthritis: an in vitro and in vivo study
Journal of Inflammation (2023)
-
Pyruvate Dehydrogenase Kinase 1 inhibition mediated oxidative phosphorylation enhancement in cartilage promotes osteoarthritis progression
BMC Musculoskeletal Disorders (2023)